AU2013318146B2 - Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium - Google Patents
Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium Download PDFInfo
- Publication number
- AU2013318146B2 AU2013318146B2 AU2013318146A AU2013318146A AU2013318146B2 AU 2013318146 B2 AU2013318146 B2 AU 2013318146B2 AU 2013318146 A AU2013318146 A AU 2013318146A AU 2013318146 A AU2013318146 A AU 2013318146A AU 2013318146 B2 AU2013318146 B2 AU 2013318146B2
- Authority
- AU
- Australia
- Prior art keywords
- trospium
- bladder
- medicament
- urine
- treatment period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001491 trospium Drugs 0.000 title claims abstract description 52
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 14
- 238000012377 drug delivery Methods 0.000 title claims abstract 7
- 208000026723 Urinary tract disease Diseases 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- 208000014001 urinary system disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 32
- 210000002700 urine Anatomy 0.000 claims abstract description 27
- 230000002459 sustained effect Effects 0.000 claims abstract 11
- 206010069632 Bladder dysfunction Diseases 0.000 claims abstract 6
- 210000005068 bladder tissue Anatomy 0.000 claims abstract 3
- 230000001225 therapeutic effect Effects 0.000 claims abstract 3
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 claims description 15
- 229960001530 trospium chloride Drugs 0.000 claims description 15
- 206010020853 Hypertonic bladder Diseases 0.000 claims 7
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 3
- 208000020629 overactive bladder Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010036018 Pollakiuria Diseases 0.000 claims 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 206010029446 nocturia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010046494 urge incontinence Diseases 0.000 claims 2
- 208000022934 urinary frequency Diseases 0.000 claims 2
- 230000036318 urination frequency Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 10
- 229960005434 oxybutynin Drugs 0.000 description 10
- 241000700159 Rattus Species 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 4
- 230000001022 anti-muscarinic effect Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 229960004045 tolterodine Drugs 0.000 description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 4
- 229960003553 tolterodine tartrate Drugs 0.000 description 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 4
- 230000036724 intravesical pressure Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960002016 oxybutynin chloride Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000003741 urothelium Anatomy 0.000 description 2
- 206010048994 Bladder spasm Diseases 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702576P | 2012-09-18 | 2012-09-18 | |
| US61/702,576 | 2012-09-18 | ||
| PCT/US2013/060479 WO2014047221A1 (en) | 2012-09-18 | 2013-09-18 | Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013318146A1 AU2013318146A1 (en) | 2015-03-19 |
| AU2013318146B2 true AU2013318146B2 (en) | 2018-05-10 |
Family
ID=49301639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013318146A Active AU2013318146B2 (en) | 2012-09-18 | 2013-09-18 | Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10500200B2 (enExample) |
| EP (1) | EP2897616A1 (enExample) |
| JP (2) | JP6600256B2 (enExample) |
| KR (1) | KR102141433B1 (enExample) |
| CN (2) | CN111450093A (enExample) |
| AU (1) | AU2013318146B2 (enExample) |
| BR (1) | BR112015005351A2 (enExample) |
| CA (1) | CA2883855C (enExample) |
| IL (1) | IL237498B (enExample) |
| MX (2) | MX379066B (enExample) |
| RU (1) | RU2670749C9 (enExample) |
| SG (1) | SG11201502104YA (enExample) |
| WO (1) | WO2014047221A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| KR102383496B1 (ko) | 2012-08-31 | 2022-04-08 | 타리스 바이오메디컬 엘엘씨 | 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법 |
| RU2657591C2 (ru) | 2012-08-31 | 2018-06-14 | ТАРИС Биомедикал ЛЛК | Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения |
| MX379066B (es) * | 2012-09-18 | 2025-03-04 | Taris Biomedical Llc | Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior. |
| CN106573133B (zh) * | 2014-08-19 | 2020-03-03 | 加利福尼亚大学董事会 | 用于局部药物递送的植入物及其使用方法 |
| GB201506526D0 (en) | 2015-04-17 | 2015-06-03 | Uropharma Ltd And Synesis Llc | Medicinal composition |
| CN106706832A (zh) * | 2015-08-06 | 2017-05-24 | 舒泰神（北京）生物制药股份有限公司 | 一种测定曲司氯铵含量的方法 |
| LT3432970T (lt) | 2017-02-01 | 2021-05-10 | Taris Biomedical Llc | In vivo vaistų vartojimo įtaisai |
| WO2019023388A1 (en) | 2017-07-25 | 2019-01-31 | Taris Biomedical Llc | METHODS OF TREATING TUMOR METASTASIS |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| CA3107461A1 (en) * | 2018-08-01 | 2020-02-06 | Taris Biomedical Llc | Methods of treating overactive bladder using trospium |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| WO2020222139A1 (en) * | 2019-04-30 | 2020-11-05 | Trigone Pharma Ltd. | Formulations and methods for drug instillation into the bladder and treatment of bladder ailments |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11338119B2 (en) | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| KR102596697B1 (ko) | 2021-05-20 | 2023-11-01 | 김정우 | 바위솔 추출물을 유효성분으로 포함하는 화장품 조성물 및 그 제조 방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998430A (en) * | 1996-11-27 | 1999-12-07 | Dr. R. Pfleger Chemische Fabrik Gmbh | Use of trospium chloride and 2-component system for the same |
| WO2006101954A2 (en) * | 2005-03-17 | 2006-09-28 | Indevus Pharmaceuticals, Inc. | Interstitial cystitis treatment |
| US20120203203A1 (en) * | 2011-02-04 | 2012-08-09 | Taris Biomedical, Inc. | Implantable device for controlled dissolution and diffusion of low solubility drug |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| WO2004052440A1 (en) * | 2002-12-11 | 2004-06-24 | Coloplast A/S | A urinary catheter device with a pharmaceutically active composition |
| AU2004206846B2 (en) | 2003-01-16 | 2009-05-28 | University Of Rochester | Quaternary antimuscarinic compounds for the treatment of bladder diseases |
| ES2322148T3 (es) | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias. |
| US7390816B2 (en) | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| US20100003297A1 (en) | 2005-08-11 | 2010-01-07 | Massachusetts Institute Of Technology | Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues |
| DK1933810T3 (da) | 2005-08-11 | 2013-01-28 | Childrens Medical Center | Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| DK2231254T3 (da) | 2007-12-11 | 2014-07-21 | Massachusetts Inst Technology | Implanterbar lægemiddelafgivelsesindretning |
| US8343516B2 (en) | 2009-06-26 | 2013-01-01 | Taris Biomedical, Inc. | Solid drug tablets for implantable drug delivery devices |
| US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| US8679094B2 (en) | 2009-12-17 | 2014-03-25 | Taris Biomedical, Inc. | Implantable device with intravesical tolerability and methods of treatment |
| US20110218488A1 (en) | 2010-03-05 | 2011-09-08 | Taris Biomedical, Inc. | Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites |
| US9457176B2 (en) | 2010-10-06 | 2016-10-04 | Taris Biomedical Llc | Implantable drug delivery device with bladder retention feature |
| US8690840B2 (en) | 2010-10-06 | 2014-04-08 | Taris Biomedical, Inc. | Time-selective bioresorbable or collapsible drug delivery systems and methods |
| US9114111B2 (en) | 2011-01-10 | 2015-08-25 | Allergan, Inc. | Methods for sustained treatment of bladder pain and irritative voiding |
| MX379066B (es) * | 2012-09-18 | 2025-03-04 | Taris Biomedical Llc | Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior. |
| SG11201507294WA (en) | 2013-03-15 | 2015-10-29 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
-
2013
- 2013-09-18 MX MX2015003110A patent/MX379066B/es unknown
- 2013-09-18 BR BR112015005351A patent/BR112015005351A2/pt not_active Application Discontinuation
- 2013-09-18 SG SG11201502104YA patent/SG11201502104YA/en unknown
- 2013-09-18 RU RU2015112196A patent/RU2670749C9/ru active
- 2013-09-18 CA CA2883855A patent/CA2883855C/en active Active
- 2013-09-18 KR KR1020157008403A patent/KR102141433B1/ko active Active
- 2013-09-18 WO PCT/US2013/060479 patent/WO2014047221A1/en not_active Ceased
- 2013-09-18 AU AU2013318146A patent/AU2013318146B2/en active Active
- 2013-09-18 EP EP13771696.5A patent/EP2897616A1/en active Pending
- 2013-09-18 CN CN202010161062.6A patent/CN111450093A/zh active Pending
- 2013-09-18 JP JP2015532177A patent/JP6600256B2/ja active Active
- 2013-09-18 CN CN201380046758.2A patent/CN104684556A/zh active Pending
-
2015
- 2015-03-02 IL IL237498A patent/IL237498B/en active IP Right Grant
- 2015-03-11 MX MX2020002465A patent/MX2020002465A/es unknown
- 2015-03-16 US US14/658,699 patent/US10500200B2/en active Active
-
2018
- 2018-02-02 JP JP2018017300A patent/JP2018080208A/ja active Pending
-
2019
- 2019-12-06 US US16/706,009 patent/US11850244B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998430A (en) * | 1996-11-27 | 1999-12-07 | Dr. R. Pfleger Chemische Fabrik Gmbh | Use of trospium chloride and 2-component system for the same |
| WO2006101954A2 (en) * | 2005-03-17 | 2006-09-28 | Indevus Pharmaceuticals, Inc. | Interstitial cystitis treatment |
| US20120203203A1 (en) * | 2011-02-04 | 2012-08-09 | Taris Biomedical, Inc. | Implantable device for controlled dissolution and diffusion of low solubility drug |
Non-Patent Citations (2)
| Title |
|---|
| MICHAELI W et al:, ANNUAL TECHNICAL CONFERENCE - ANTEC 2009, , SOCIETY OF PLASTICS ENGINEERS USA, 2009, Vol. 5, pages 2951-2956, * |
| VON WALTER M et al: " TROSPIUM CHLORIDE RELEASED FROM INTRAVESICALLY APPLIED PLGA-BASED CARRIERS DECREASES BLADDER CONTRACTILITY IN AN ISOLATED WHOLE PIG BLADDER MODEL", EUROPEAN UROLOGY SUPPLEMENTS, 2009, 230, Vol. 8, no. 4, page 178 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2883855A1 (en) | 2014-03-27 |
| JP6600256B2 (ja) | 2019-10-30 |
| KR102141433B1 (ko) | 2020-08-05 |
| US11850244B2 (en) | 2023-12-26 |
| MX379066B (es) | 2025-03-04 |
| JP2015529688A (ja) | 2015-10-08 |
| CA2883855C (en) | 2020-09-15 |
| WO2014047221A9 (en) | 2015-05-21 |
| MX2020002465A (es) | 2020-07-13 |
| AU2013318146A1 (en) | 2015-03-19 |
| SG11201502104YA (en) | 2015-05-28 |
| WO2014047221A1 (en) | 2014-03-27 |
| RU2670749C9 (ru) | 2018-12-13 |
| CN111450093A (zh) | 2020-07-28 |
| US10500200B2 (en) | 2019-12-10 |
| KR20150058271A (ko) | 2015-05-28 |
| US20200108057A1 (en) | 2020-04-09 |
| EP2897616A1 (en) | 2015-07-29 |
| RU2670749C2 (ru) | 2018-10-25 |
| MX2015003110A (es) | 2015-06-05 |
| IL237498B (en) | 2018-01-31 |
| CN104684556A (zh) | 2015-06-03 |
| RU2015112196A (ru) | 2016-11-10 |
| US20150182516A1 (en) | 2015-07-02 |
| JP2018080208A (ja) | 2018-05-24 |
| IL237498A0 (en) | 2015-04-30 |
| BR112015005351A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013318146B2 (en) | Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium | |
| KR102157548B1 (ko) | 방광암의 치료를 위한 옥살리플라틴을 포함하는 약물 전달 시스템과 방법 | |
| KR102383496B1 (ko) | 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법 | |
| JP2015529688A5 (enExample) | ||
| HK40026424A (en) | Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium | |
| HK40042011A (en) | Drug delivery systems and methods for treatment of prostate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |